Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis

Torkian, Pooya; Mansoori, Bahar; Hillengaß, Jens; Azadbakht, Javid; Rashedi, Sina; Lee, Sarah S.; Amini, Behrang; Bonaffini, Pietro Andrea; Chalian, Majid

doi:10.1007/s00256-022-04119-0

Cited by 8 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After therapy, the sensitivity of BM samples is reduced because marrow involvement in MM could be patchy, while MRI shows a better assessment for detecting diffuse marrow involvement, correlating with response to therapy [50]. WB-MRI assesses water and fat in tissues and it can detect BM abnormalities before significant bone destruction.…”

Section: Mri: Methods and Role In Response To Therapy In MMmentioning

confidence: 99%

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI

Santoni

Simoncelli

Franceschini

et al. 2022

JPM

View full text Add to dashboard Cite

Bone disease is among the defining characteristics of symptomatic Multiple Myeloma (MM). Imaging techniques such as fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET/CT) and magnetic resonance imaging (MRI) can identify plasma cell proliferation and quantify disease activity. This function renders these imaging tools as suitable not only for diagnosis, but also for the assessment of bone disease after treatment of MM patients. The aim of this article is to review FDG PET/CT and MRI and their applications, with a focus on their role in treatment response evaluation. MRI emerges as the technique with the highest sensitivity in lesions’ detection and PET/CT as the technique with a major impact on prognosis. Their comparison yields different results concerning the best tool to evaluate treatment response. The inhomogeneity of the data suggests the need to address limitations related to these tools with the employment of new techniques and the potential for a complementary use of both PET/CT and MRI to refine the sensitivity and achieve the standards for minimal residual disease (MRD) evaluation.

show abstract

Section: Mri: Methods and Role In Response To Therapy In MMmentioning

confidence: 99%

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI

Santoni

Simoncelli

Franceschini

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Change in ADC has shown promise as an early treatment response marker in various tumors, including nasopharyngeal carcinoma. [16][17][18][19]…”

Section: Application Examplementioning

confidence: 99%

A statistical framework for planning and analysing test–retest studies of repeatability

Danzer,

Eveslage,

Görlich

et al. 2024

Stat Methods Med Res

View full text Add to dashboard Cite

There is an increasing number of potential quantitative biomarkers that could allow for early assessment of treatment response or disease progression. However, measurements of such biomarkers are subject to random variability. Hence, differences of a biomarker in longitudinal measurements do not necessarily represent real change but might be caused by this random measurement variability. Before utilizing a quantitative biomarker in longitudinal studies, it is therefore essential to assess the measurement repeatability. Measurement repeatability obtained from test–retest studies can be quantified by the repeatability coefficient, which is then used in the subsequent longitudinal study to determine if a measured difference represents real change or is within the range of expected random measurement variability. The quality of the point estimate of the repeatability coefficient, therefore, directly governs the assessment quality of the longitudinal study. Repeatability coefficient estimation accuracy depends on the case number in the test–retest study, but despite its pivotal role, no comprehensive framework for sample size calculation of test–retest studies exists. To address this issue, we have established such a framework, which allows for flexible sample size calculation of test–retest studies, based upon newly introduced criteria concerning assessment quality in the longitudinal study. This also permits retrospective assessment of prior test–retest studies.

show abstract

“…A 33% increase in ADC helped identify response with 90% sensitivity and 100% specificity. Two recent meta-analyses confirmed that a 35% increase in ADC from baseline values is found to classify response post-induction chemotherapy [ 39 ], and ADC had a pooled sensitivity of 78% and specificity of 73% in distinguishing responders from non-responders [ 40 ]. Zhang et al [ 41 ] studied the correlation between baseline ADC values and survival in MM patients.…”

Section: Wbmrimentioning

confidence: 99%

“…DWI with suppression of background body signals can detect lesions more reliably with high sensitivity than FDG-PET/CT, albeit at the expense of specificity. DWI had a pooled sensitivity of 78% and specificity of 73% in distinguishing responders from non-responders, emphasizing the importance of DWI for treatment response assessment in patients with MM [ 40 ].…”

Section: Petmentioning

confidence: 99%

Imaging of Multiple Myeloma: Present and Future

Rodríguez-Laval,

Lumbreras-Fernández,

Aguado-Bueno

et al. 2024

JCM

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common adult hematologic malignancy, and early intervention increases survival in asymptomatic high-risk patients. Imaging is crucial for the diagnosis and follow-up of MM, as the detection of bone and bone marrow lesions often dictates the decision to start treatment. Low-dose whole-body computed tomography (CT) is the modality of choice for the initial assessment, and dual-energy CT is a developing technique with the potential for detecting non-lytic marrow infiltration and evaluating the response to treatment. Magnetic resonance imaging (MRI) is more sensitive and specific than 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the detection of small focal lesions and diffuse marrow infiltration. However, FDG-PET/CT is recommended as the modality of choice for follow-up. Recently, diffusion-weighted MRI has become a new technique for the quantitative assessment of disease burden and therapy response. Although not widespread, we address current proposals for structured reporting to promote standardization and diminish variations. This review provides an up-to-date overview of MM imaging, indications, advantages, limitations, and recommended reporting of each technique. We also cover the main differential diagnosis and pitfalls and discuss the ongoing controversies and future directions, such as PET-MRI and artificial intelligence.

show abstract

Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis

Cited by 8 publications

References 61 publications

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI

A statistical framework for planning and analysing test–retest studies of repeatability

Imaging of Multiple Myeloma: Present and Future

Contact Info

Product

Resources

About